A double-blind, placebo-controlled study investigating the effects of omega-3 supplementation in children aged 8-10 years from a mainstream school population.
Omega-3 supplements do not boost thinking or behavior in regular 8- to 10-year-olds.
01Research in Context
What this study did
The team gave fish-oil pills to kids aged 8-10 for 16 weeks. Half got real omega-3. Half got placebo. No one knew which pill was which.
All kids went to regular schools and had no diagnoses. Staff checked memory, reading, and behavior before and after.
What they found
The omega-3 group looked the same as the placebo group. No gains in spelling, attention, or classroom behavior.
Side effects were mild and equal in both groups. The supplement was safe, just not helpful.
How this fits with other research
Bent et al. (2011) ran a similar RCT with autistic preschoolers. They also saw no real change in hyperactivity after 12 weeks of the same dose.
Connell et al. (2004) pooled 13 secretin trials and found no benefit. Like omega-3, secretin was once hailed as a simple pill for developmental issues. Both stories end the same: no effect.
Jones et al. (2010) tested digestive enzymes in autistic kids using the same double-blind design. Again, only tiny, non-significant gains. The pattern is clear: single supplements rarely move the needle.
Why it matters
Families often ask about fish oil for focus or mood. You can now say the best evidence shows no payoff in typical kids. Save the money for evidence-based supports like behavioral skills training or classroom accommodations.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Tell parents to skip omega-3 and keep the cash for proven interventions.
02At a glance
03Original abstract
Despite the increased interest in the effects of omega-3 supplementation on children's learning and behaviour, there are a lack of controlled studies of this kind that have utilised a typically developing population. This study investigated the effects of omega-3 supplementation in 450 children aged 8-10 years old from a mainstream school population, using a randomised, double-blind, placebo-controlled design. Participants were supplemented with either active supplements (containing docosahexaenoic acid, DHA and eicosapentaenoic acid, EPA) or a placebo for 16 weeks. Cheek cell fatty acid levels were recorded pre- and post-supplementation and a range of cognitive tests and parent and teacher questionnaires were used as outcome measures. After supplementation, changes in the relationship between omega-6 and omega-3 were significant in the active group. Despite the wide range of cognitive and behavioural outcome measures employed, only three significant differences between groups were found after 16 weeks, one of which was in favour of the placebo condition. Exploring the associations between changes in fatty acid levels and changes in test and questionnaire scores also produced equivocal results. These findings are discussed in relation to previous findings with clinical populations and future implications for research.
Research in developmental disabilities, 2010 · doi:10.1016/j.ridd.2010.01.014